Глюренорм®

General characteristics. Structure:

Active agent: 30 mg of a glikvidon.

Excipients: lactose the monohydrate, starch which corn is dried up starch corn soluble, magnesium stearate.

Pharmacological properties:

Pharmacodynamics. Glyurenorm stimulates products of insulin with pancreas beta cells.

Pharmacokinetics. Glikvidon is quickly and almost completely soaked up from a GIT. After intake of a single dose of Glyurenorm (30 mg) the maximum concentration of drug in plasma is reached in 2-3 hours, makes 500 - 700 ng/ml and in ½-1 hour decreases by 50%.

Glyurenorm is completely metabolized by a liver. The main part of metabolites is removed with bile and a stake. With urine only a small part of metabolites is removed. Irrespective of a dose and a way of introduction, in urine about 5% (in the form of metabolites) the entered amount of drug are found. Level of removal of Glyurenorm with urine remains minimum even at regular appointment.

Indications to use:

Diabetes mellitus of type 2 at patients of middle and advanced age (at inefficiency of a dietotherapy).

Route of administration and doses:

It is necessary to observe strictly the recommendations of the doctor submitted on normalization of carbohydrate metabolism at the patient. It is not necessary to stop treatment independently, without having reported about it to the doctor. The initial dose of Glyurenorm usually makes ½ tablets (15 mg) during a breakfast. If necessary the dose is raised gradually, according to recommendations of the doctor.

Increase in a dose usually does not lead more than 4 tablets (120 mg) a day to further strengthening of effect.

When replacing peroral gipoglikemiziruyushchy means with the similar mechanism of action the initial dose is defined depending on the course of a disease at the time of purpose of drug. The initial dose usually makes ½-1 tablet (15-30 mg). The dose is increased only according to the recommendation of the doctor.

If the daily dose of Glyurenorm does not exceed 2 tablets (60 mg), it can be appointed in one step, during a breakfast. However, the best effect is reached at purpose of drug 2-3 times a day. Glyurenorm it is necessary to accept during food, at the beginning of meal.

Features of use:

Though Glyurenorm is brought with urine in insignificant quantities (5%) and usually well had at diseases of kidneys, treatment of patients with the expressed renal failure should be carried out under careful medical observation.

In case of pregnancy emergence, it is necessary to stop administration of drug and to see immediately a doctor. In need of use of drug during breastfeeding, feeding by a breast should be stopped.

The patients suffering from a diabetes mellitus are inclined to development of cardiovascular disturbances. The risk can be reduced only at strict observance of the ordered diet. Peroral hypoglycemic means should not replace a medical diet which allows to control the body weight of the patient and is obligatory regardless of use of this or that drug. All peroral hypoglycemic means at untimely meal or non-compliance with the recommended mode of dosing can give to considerable decrease in level of glucose in blood and loss of ability to concentration. The use of sugar, candies or sweet drinks usually helps to prevent the beginning hypoglycemic reaction. In case of the remaining hypoglycemic state it is necessary to see a doctor immediately.

In case of an indisposition during treatment by Glyurenorm (fevers, rashes, nausea), it is necessary to see a doctor immediately. In case of development of allergic reactions, it is necessary to stop Glyurenorm's reception, having replaced it with other hypoglycemic drug or insulin.

Influence on ability to driving of motor transport and to control of mechanisms. During selection of a dose or change of drug it is necessary to avoid occupations potentially dangerous types of activity requiring special attention and speed of psychomotor reactions.

Side effects:

Seldom: hypoglycemic reactions, skin allergic reactions, changes of the hemopoietic system and frustration from digestive tract.

Interaction with other medicines:

The salicylates, streptocides derivative of phenylbutazone, antitubercular drugs, chloramphenicol, tetracyclines and derivatives of coumarin, cyclophosphamides, MAO inhibitors and β-adrenoblockers, can strengthen hypoglycemic action of derivatives of sulphonylurea.

Reduction of hypoglycemic action at the co-administration of Glyurenorm and Chlorpromazinum, sympathomimetics, glyukortikosteroid, thyroid hormones, oral contraceptives and drugs containing niacin is possible.

Glyurenorm can reduce tolerance to alcohol.

Contraindications:

• diabetes mellitus of 1 type,

• diabetic ketoacidosis, prekoma, coma;

• hypersensitivity to derivatives of sulphonylurea or to streptocides;

• pregnancy, breastfeeding period.

Overdose:

Hypoglycemic states are possible. In case of development of a hypoglycemic state immediate administration of glucose inside or intravenously is necessary.

Storage conditions:

In the dry place, at a temperature not above 25 °C. To store in the place, unavailable to children! Period of validity of 5 years. Not to apply after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Tablets of 30 mg. On 10 tablets in a blister strip packaging (blister) from PVC/Al. On 3, 6 or 12 blisters with the application instruction in a cardboard pack.